Work

Lysosomal Lipid Dysregulation in Parkinson's Disease: Genetic and Medication Effects in CSF Metabolomics

Year: 2025

Type: article

Abstract: Parkinson's disease (PD) is a heterogeneous neurodegenerative disorder with clinical and molecular diversity across genetic and sporadic forms. Cerebrospinal fluid (CSF) metabolomics provides direct access to brain biochemistry, enabling investigation of metabolic pathways disrupted in disease. This analysis aims to identify metabolic signatures distinguishing sporadic PD (sPD), LRRK2-PD, and GBA-PD, and reveal shared and distinct biochemical processes underlying disease pathogenesis.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.17127218

Authors: Suh, Jung H., Maciuca, Romeo, Davis, Sonnet, Kluss, Jillian H., Yazd, Hoda Safari, Alkabsh, Jamal, Schwarzchild, Michael, Huntwork-Rodriguez, Sarah

Institutions: Denali Therapeutics (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Harvard University, Massachusetts General Hospital

Language: English

Topic: Parkinson's Disease Mechanisms and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7081632445

FWCI:

Cites:

Cited by:

Related to: